Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ensysce Biosciences, Inc. (ENSC)
USD0.29
0.00 (-0.38%)
US NASDAQ Healthcare Biotechnology
Address
7946 Ivanhoe Avenue 92037
La Jolla, CA, US
La Jolla, CA, US
CEO
D. Lynn Kirkpatrick
Website
ensysce.com
IPO
2018-03-14
CIK 1716947 ISIN US2936025046
Also trades on
NASDAQ Capital Market · ENSC (USD)
Other OTC · ENSCW (USD)
Description
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.29
0.00 (-0.38%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.82
Float Shares
9.25M
Free Float %
99.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.05% | -25.64% | -43.98% | -35.46% | -85.71% | -69.55% | -89.02% | -99.36% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
0.29
DCF (Unlevered)
156,535.97
+53,718,489.6%
DCF (Levered)
156,534.88
+53,718,116.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-108.23
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-2.8% Q1'26: -27.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+12.9% Q1'26: +62.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-170.8% Q1'26: -364.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-200.5% Q1'26: -370.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +1,219.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1,363.9% Q1'26: +388.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-30,214.90× Q1'26: -0.02× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
3.53M
est: 2.70M (+30.8%)
|
2.52M
est: 2.64M (-4.3%)
|
2.23M
est: 1.44M (+55.2%)
|
5.21M
est: 4.15M (+25.5%)
|
5.07M
est: 3.70M (+36.9%)
|
7.70M
7.70M – 7.70M
+108.1% YoY
|
2.50M
2.50M – 2.50M
-67.5% YoY
|
| EBITDA |
-25.93M
est: -2.05M (-1,167.8%)
|
-24.22M
est: -2.00M (-1,112.7%)
|
-10.72M
est: -1.44M (-645.4%)
|
-6.73M
est: -4.15M (-62.2%)
|
-10.15M
est: -3.70M (-174.3%)
|
-7.70M
-7.70M – -7.70M
-108.1% YoY
|
-2.50M
-2.50M – -2.50M
+67.5% YoY
|
| EBIT |
-25.93M
est: -2.05M (-1,167.8%)
|
-24.22M
est: -2.00M (-1,112.7%)
|
-10.72M
est: -1.44M (-645.4%)
|
-6.73M
est: -4.15M (-62.2%)
|
-10.16M
est: -3.70M (-174.5%)
|
-7.70M
-7.70M – -7.70M
-108.1% YoY
|
-2.50M
-2.50M – -2.50M
+67.5% YoY
|
| Net Income |
-29.08M
est: -194.97M (+85.1%)
|
-24.17M
est: -3.15B (+99.2%)
|
-10.61M
est: -54.94M (+80.7%)
|
-7.99M
est: -213.16M (+96.3%)
|
-10.18M
est: -120.97M (+91.6%)
|
-90.53M
-90.53M – -90.53M
+25.2% YoY
|
-5.11M
-5.11M – -5.11M
+94.4% YoY
|
| SGA |
18.71M
est: 6.29M (+197.7%)
|
6.91M
est: 6.14M (+12.6%)
|
5.36M
est: 279.87B (-100.0%)
|
4.72M
est: 807.74B (-100.0%)
|
4.93T
est: 720.15B (+584.7%)
|
1.50T
1.50T – 1.50T
+108.1% YoY
|
486.59B
486.59B – 486.59B
-67.5% YoY
|
| EPS |
-355.68
est: -111.60 (-218.7%)
|
-139.44
est: -1,803.00 (+92.3%)
|
-4.69
est: -2.15 (-118.3%)
|
-4.57
est: -8.34 (+45.2%)
|
-3.98
est: -4.73 (+15.9%)
|
-3.54
-3.54 – -3.54
+25.2% YoY
|
-0.20
-0.20 – -0.20
+94.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-12 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-887.75M
OE per share TTM
1,672.09
Owner's Yield
-120,467.02%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
613,627.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
40
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | G. Gower | 7.93M | 32.60% | 7.93M | — | 7.93M | — | IN | States | 2021-07-12 | ↗ |
| 2 | Lane Capital Partners LLC | 2.88M | 11.08% | 2.88M | — | 2.88M | 10.00 | OO | Delaware | 2021-07-06 | ↗ |
| 3 | Silvers | 2.88M | 11.08% | 2.88M | — | 2.88M | 10.00 | IN | of America | 2021-07-06 | ↗ |
| 4 | Daniel B. Silvers | 2.88M | 7.90% | 2.88M | — | 2.88M | — | IN | United States of America | 2022-07-07 | ↗ |
| 5 | Matthews Lane Capital Partners LLC | 2.88M | 7.90% | 2.88M | — | 2.88M | — | OO | Delaware | 2022-07-07 | ↗ |
| 6 | GLL Funding LLC | 2.64M | 10.15% | 2.64M | — | 2.64M | 10.00 | OO | Delaware | 2021-07-06 | ↗ |
| 7 | MLCP GLL Funding LLC | 2.64M | 7.30% | 2.64M | — | 2.64M | — | OO | Delaware | 2022-07-07 | ↗ |
| 8 | Lynn Kirkpatrick | 2.60M | 9.80% | 2.60M | — | 2.60M | — | IN | United States | 2021-07-12 | ↗ |
| 9 | William Chang | 2.60M | 10.70% | — | 2.60M | — | 2.60M | IN | United States | 2021-07-12 | ↗ |
| 10 | Hydra LAC, LLC | 1.87M | 7.39% | 1.87M | — | 1.87M | — | OO | Canada | 2021-07-07 | ↗ |
| 11 | BMO Capital Markets Corp. | 1.56M | 6.23% | 1.56M | — | 1.56M | — | FI | — | 2020-02-14 | ↗ |
| 12 | Bank Of Montreal | 1.56M | 6.23% | 1.56M | — | 1.56M | — | HC | — | 2020-02-14 | ↗ |
| 13 | Alex Noah Investors, Inc. | 1.50M | 9.99% | — | 1.50M | — | 1.50M | CO | Illinois | 2023-02-07 | ↗ |
| 14 | Jonathan I. Cope | 1.50M | 9.99% | — | 1.50M | — | 1.50M | IN | United States | 2023-02-07 | ↗ |
| 15 | Joshua B. Scheinfeld | 1.50M | 9.99% | — | 1.50M | — | 1.50M | IN | United States | 2023-02-07 | ↗ |
| 16 | Lincoln Park Capital Fund, LLC | 1.50M | 9.99% | — | 1.50M | — | 1.50M | OO | Illinois | 2023-02-07 | ↗ |
| 17 | Lincoln Park Capital, LLC | 1.50M | 9.99% | — | 1.50M | — | 1.50M | OO | Illinois | 2023-02-07 | ↗ |
| 18 | Rockledge Capital Corporation | 1.50M | 9.99% | — | 1.50M | — | 1.50M | OO | Texas | 2023-02-07 | ↗ |
| 19 | Peter Kolchinsky | 1.48M | 9.90% | — | 1.48M | — | — | HC, IN | Delaware | 2024-11-06 | ↗ |
| 20 | RA Capital Healthcare Fund, L.P. | 1.48M | 9.90% | — | 1.48M | — | — | PN | Delaware | 2024-11-06 | ↗ |
| 21 | RA Capital Management, L.P. | 1.48M | 9.90% | — | 1.48M | — | — | IA, PN | Delaware | 2024-11-06 | ↗ |
| 22 | Rajeev Shah | 1.48M | 9.90% | — | 1.48M | — | — | HC, IN | Delaware | 2024-11-06 | ↗ |
| 23 | Wright | 1.39M | 5.40% | 1.39M | — | 1.39M | — | IN | States | 2021-07-12 | ↗ |
| 24 | Joseph Edelman | 1.30M | 8.70% | — | 1.30M | — | 1.30M | IN | Delaware | 2024-10-29 | ↗ |
| 25 | Perceptive Advisors LLC | 1.30M | 8.70% | — | 1.30M | — | 1.30M | IA | Delaware | 2024-10-29 | ↗ |
| 26 | Perceptive Life Sciences Master Fund, Ltd. | 1.30M | 8.70% | — | 1.30M | — | 1.30M | CO | Delaware | 2024-10-29 | ↗ |
| 27 | A. Lorne Weil | 1.13M | 18.20% | 266.9K | 867.8K | 266.9K | 867.8K | IN | Delaware | 2021-02-10 | ↗ |
| 28 | Amin Nathoo | 983.5K | 7.10% | — | 983.5K | — | 983.5K | HC, IN | Texas | 2024-11-14 | ↗ |
| 29 | Anson Advisors Inc. | 983.5K | 7.10% | — | 983.5K | — | 983.5K | FI, CO | Texas | 2024-11-14 | ↗ |
| 30 | Anson Funds Management LP | 983.5K | 7.10% | — | 983.5K | — | 983.5K | IA, PN | Texas | 2024-11-14 | ↗ |
| 31 | Anson Management GP LLC | 983.5K | 7.10% | — | 983.5K | — | 983.5K | HC, OO | Texas | 2024-11-14 | ↗ |
| 32 | Moez Kassam | 983.5K | 7.10% | — | 983.5K | — | 983.5K | HC, IN | Texas | 2024-11-14 | ↗ |
| 33 | Tony Moore | 983.5K | 7.10% | — | 983.5K | — | 983.5K | HC, IN | Texas | 2024-11-14 | ↗ |
| 34 | AQR Capital Management Holdings, LLC | 550.0K | 2.20% | — | 550.0K | — | — | HC | Delaware, USA | 2019-02-15 | ↗ |
| 35 | CNH Partners, LLC | 550.0K | 2.20% | — | 550.0K | — | — | IA | Delaware, USA | 2019-02-15 | ↗ |
| 36 | CVI Investments, Inc. | 500.0K | 7.80% | — | 500.0K | — | 500.0K | CO | Cayman Islands | 2022-12-16 | ↗ |
| 37 | Heights Capital Management, Inc. | 500.0K | 7.80% | — | 500.0K | — | 500.0K | CO | Cayman Islands | 2022-12-16 | ↗ |
| 38 | Glazer Capital, LLC | — | 0.00% | — | — | — | — | IA, OO | State of Delaware | 2022-02-14 | ↗ |
| 39 | Notes). | — | 0.00% | — | — | — | — | IA | DELAWARE | 2021-02-11 | ↗ |
| 40 | Paul J. Glazer | — | 0.00% | — | — | — | — | IN | United States | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 3.5K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
3
Sells
0
Shares acquired
469.6K
Shares disposed
—
Cash buys
3.00
Cash sales
—
Net activity
+469,587
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-02 | GOWER BOB G | Director | P-Purchase | A | Common Stock | 90,287 | 0.49 | 44.1K | 1,222,682 | — | ↗ |
| 2023-03-01 | GOWER BOB G | Director | P-Purchase | A | Common Stock | 270,000 | 0.48 | 129.0K | 1,132,395 | — | ↗ |
| 2023-02-28 | GOWER BOB G | Director | P-Purchase | A | Common Stock | 109,300 | 0.49 | 53.4K | 862,395 | — | ↗ |
| 2022-12-09 | GOWER BOB G | Director | P-Purchase | A | Common Stock | 357,143 | 1.40 | 500.0K | 753,095 | — | ↗ |
| 2022-06-23 | Rosebraugh Curtis | Director | A-Award | A | Stock Option | 20,000 | 0.00 | — | 35,000 | — | ↗ |
| 2022-06-23 | Rauch Lee M. | Director | A-Award | A | Stock Option | 15,000 | 0.00 | — | 35,000 | — | ↗ |
| 2022-06-23 | Martin Steven Robert | Director | A-Award | A | Stock Option | 15,000 | 0.00 | — | 100,850 | — | ↗ |
| 2022-06-23 | Levin Adam | Director | A-Award | A | Stock Option | 15,000 | 0.00 | — | 35,000 | — | ↗ |
| 2022-06-23 | GOWER BOB G | Director / 10% Owner | A-Award | A | Stock Option | 15,000 | 0.43 | 6.4K | 41,585 | — | ↗ |
| 2022-06-23 | Chang William H | Director | A-Award | A | Stock Option | 15,000 | 0.00 | — | 35,000 | — | ↗ |
| 2022-06-23 | Benton Andrew | Director | A-Award | A | Stock Option | 15,000 | 0.00 | — | 100,850 | — | ↗ |
| 2022-05-25 | Kirkpatrick Lynn | Officer | A-Award | A | Stock Option | 200,000 | 0.00 | — | 2,516,939 | — | ↗ |
| 2022-04-18 | Osman Nilab | Officer | — | D | Stock Option | 200,000 | 1.07 | 214.0K | 0 | — | ↗ |
| 2022-02-17 | Kirkpatrick Lynn | Director / Officer | A-Award | A | Stock Option | 200,000 | 1.40 | 280.0K | 200,000 | — | ↗ |
| 2022-02-17 | Humphrey David Carl | Officer | A-Award | A | Stock Option | 80,000 | 1.40 | 112.0K | 80,000 | — | ↗ |
| 2022-02-17 | Birkett Kevin Geoffrey | Officer | A-Award | A | Stock Option | 50,000 | 1.40 | 70.0K | 50,000 | — | ↗ |
| 2022-02-08 | Rauch Lee M. | Director | — | D | Stock Option | 20,000 | 1.70 | 34.0K | 0 | — | ↗ |
| 2022-02-04 | Rosebraugh Curtis | Director | A-Award | A | Stock Option | 20,000 | 3.13 | 62.6K | 20,000 | — | ↗ |
| 2022-02-04 | Pestano Linda | Officer | A-Award | A | Stock Option | 200,000 | 2.48 | 496.0K | 200,000 | — | ↗ |
| 2022-02-04 | Martin Steven Robert | Director | A-Award | A | Stock Option | 20,000 | 3.13 | 62.6K | 20,000 | — | ↗ |
| 2022-02-04 | Levin Adam | Director | A-Award | A | Stock Option | 20,000 | 3.13 | 62.6K | 20,000 | — | ↗ |
| 2022-02-04 | Humphrey David Carl | Officer | A-Award | A | Stock Option | 275,000 | 3.13 | 860.8K | 275,000 | — | ↗ |
| 2022-02-04 | GOWER BOB G | Director / 10% Owner | A-Award | A | Stock Option | 20,000 | 3.13 | 62.6K | 20,000 | — | ↗ |
| 2022-02-04 | Chang William H | Director / 10% Owner | A-Award | A | Stock Option | 20,000 | 3.13 | 62.6K | 20,000 | — | ↗ |
| 2022-02-04 | Benton Andrew | Director | A-Award | A | Stock Option | 20,000 | 3.13 | 62.6K | 20,000 | — | ↗ |
| 2021-10-15 | Pestano Linda | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-30 | Wright Richard Chester | Officer | A-Award | A | Stock Option | 49,975 | 0.00 | — | 49,975 | — | ↗ |
| 2021-06-30 | WEIL A LORNE | 10% Owner | D-Return | D | Warrants | 250,000 | 11.50 | 2.88M | 137,895 | — | ↗ |
| 2021-06-30 | Silvers Daniel B. | 10% Owner | A-Award | A | Warrants | 1,637,390 | 11.50 | 18.83M | 1,637,390 | — | ↗ |
| 2021-06-30 | Schmidt William K | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-30 | Rosebraugh Curtis | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-30 | Peng George | — | A-Award | A | Warrants | 15,000 | 11.50 | 172.5K | 15,000 | — | ↗ |
| 2021-06-30 | Millard Jeffrey | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-30 | Martin Steven Robert | Director | A-Award | A | Stock Option | 65,850 | 3.35 | 220.6K | 65,850 | — | ↗ |
| 2021-06-30 | Levin Adam | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-30 | Kirkpatrick Lynn | Director / Officer | A-Award | A | Stock Option | 263,400 | 3.19 | 840.2K | 263,400 | — | ↗ |
| 2021-06-30 | Humphrey David Carl | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2021-06-30 | GOWER BOB G | Director / 10% Owner | A-Award | A | Stock Option | 6,585 | 2.59 | 17.1K | 6,585 | — | ↗ |
| 2021-06-30 | Chang William H | Director / 10% Owner | A-Award | A | Common Stock | 353,451 | 0.00 | — | 353,451 | — | ↗ |
| 2021-06-30 | Carrera Eric | — | A-Award | A | Warrants | 30,000 | 11.50 | 345.0K | 30,000 | — | ↗ |
| 2021-06-30 | Birkett Kevin Geoffrey | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-30 | Benton Andrew | Director | A-Award | A | Stock Option | 65,850 | 3.35 | 220.6K | 65,850 | — | ↗ |
| 2020-06-19 | MORGAN STANLEY | 10% Owner | S-Sale | D | Common Stock | 776,290 | 10.44 | 8.10M | 0 | — | ↗ |
| 2020-03-29 | MORGAN STANLEY | 10% Owner | — | I | Warrants to purchase one share of Common Stock | 388,145 | 0.00 | — | 0 | — | ↗ |
| 2018-01-15 | WEIL A LORNE | Director / Officer | J-Other | D | Common Stock | 132,158 | 0.00 | — | 867,842 | — | ↗ |
| 2018-01-15 | Silvers Daniel B. | Director / Officer | J-Other | D | Common Stock | 171,832 | 0.00 | — | 1,128,370 | — | ↗ |
| 2018-01-15 | Peng George | Officer | J-Other | D | Common Stock | 13,251 | 0.00 | — | 87,014 | — | ↗ |
| 2018-01-15 | HG Vora Capital Management, LLC | 10% Owner | J-Other | D | Common Stock | 375,000 | 0.00 | — | 3,462,500 | — | ↗ |
| 2018-01-15 | Carrera Eric | Officer | J-Other | D | Common Stock | 8,330 | 0.00 | — | 54,701 | — | ↗ |
| 2017-12-05 | WEIL A LORNE | Director / Officer | J-Other | D | Common Stock | 169,517 | 0.00 | — | 1,000,000 | — | ↗ |
| 2017-12-05 | Silvers Daniel B. | Director / Officer | J-Other | D | Common Stock | 359,869 | 0.00 | — | 1,300,202 | — | ↗ |
| 2017-12-05 | Peng George | Officer | J-Other | D | Common Stock | 733 | 0.00 | — | 100,265 | — | ↗ |
| 2017-12-05 | HG Vora Capital Management, LLC | 10% Owner | J-Other | D | Common Stock | 718,750 | 0.00 | — | 2,837,500 | — | ↗ |
| 2017-12-05 | Carrera Eric | Officer | J-Other | D | Common Stock | 1,465 | 0.00 | — | 63,031 | — | ↗ |
| 2017-12-01 | Weinstein David L. | Director | — | D | Common Stock | 0 | 0.00 | — | 25,000 | — | ↗ |
| 2017-12-01 | WEIL A LORNE | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,169,517 | — | ↗ |
| 2017-12-01 | Silvers Daniel B. | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,660,071 | — | ↗ |
| 2017-12-01 | Rittvo Steven M | Director | — | D | Common Stock | 0 | 0.00 | — | 25,000 | — | ↗ |
| 2017-12-01 | Peng George | Officer | — | D | Common Stock | 0 | 0.00 | — | 100,998 | — | ↗ |
| 2017-12-01 | HG Vora Capital Management, LLC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 3,556,250 | — | ↗ |
| 2017-12-01 | Falcone Marc J. | Director | — | D | Common Stock | 0 | 0.00 | — | 25,000 | — | ↗ |
| 2017-12-01 | Carrera Eric | Officer | — | D | Common Stock | 0 | 0.00 | — | 64,496 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-14.5K
Shares Outstanding
9.28M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Dr. Lynn Kirkpatrick, PhD. Chief Executive Officer | 432.0K | — | — | — | — | 10.4K | 442.4K | 0.00% | ↗ |
| 2 | 2024 | Dave Humphrey Chief Financial Officer | 360.9K | — | — | — | — | 10.4K | 371.3K | 0.00% | ↗ |
| 3 | 2024 | Geoff Birkett Chief Commercial Officer | 333.6K | — | — | — | — | 10.0K | 343.6K | 0.00% | ↗ |
| 4 | 2023 | Dr. Lynn Kirkpatrick, PhD. Chief Executive Officer | 404.9K | — | 93.8K | — | — | 9.9K | 508.6K | 18.44% | ↗ |
| 5 | 2023 | Dave Humphrey Chief Financial Officer | 338.3K | — | 93.8K | — | — | 9.9K | 442.0K | 21.22% | ↗ |
| 6 | 2023 | Geoff Birkett Chief Commercial Officer | 312.6K | — | 70.4K | — | — | 9.4K | 392.4K | 17.93% | ↗ |
| 7 | 2021 | Dr. Lynn Kirkpatrick, PhD. Chief Executive Officer | 174.1K | 114.0K | — | — | — | — | 288.1K | 0.00% | ↗ |
| 8 | 2021 | David Humphrey Chief Financial Officer | 187.6K | 96.0K | — | — | — | — | 283.6K | 0.00% | ↗ |
| 9 | 2021 | Geoff Birkett Chief Commercial Officer | 135.0K | — | — | — | — | — | 135.0K | 0.00% | ↗ |
| 10 | 2020 | Dr. Lynn Kirkpatrick, PhD. Chief Executive Officer | 155.9K | — | — | — | — | — | 155.9K | 0.00% | ↗ |
| 11 | 2020 | Geoff Birkett Chief Commercial Officer | 72.0K | — | — | — | — | — | 72.0K | 0.00% | ↗ |
| 12 | 2020 | David Humphrey Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| D. Lynn Kirkpatrick | President, Chief Executive Officer & Director | 464.2K | — |
| David C. Humphrey | Chief Financial Officer, Secretary & Treasurer | 389.5K | male |
| Geoffrey Birkett | Chief Commercial Officer | 360.8K | male |
| Jeffrey Millard | Chief Operating Officer | — | — |
| Linda Pestano | Chief Development Officer | — | — |
| William K. Schmidt | Chairman of Clinical Advisory Board & Chief Medical Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ENSC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
